Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 7:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2305–2328 of 10,816 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Developmental Defect Clear all
Completed Phase 2 Interventional

Idebenone to Treat Friedreich's Ataxia

NCT00229632
View directory record Official record
Conditions
Friedreich Ataxia
Interventions
Idebenone
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
9 Years to 17 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Oct 31, 2026, 7:54 PM EDT
Not listed Not applicable Interventional

Evaluation of Efficacy and Tolerability of Hizentra®

NCT01354587
View directory record Official record
Conditions
Primary Immunodeficiency Disorders
Interventions
Hizentra
Drug
Lead sponsor
University of South Florida
Other
Eligibility
1 Year to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Jul 17, 2012 · Synced Oct 31, 2026, 7:54 PM EDT
Active, not recruiting Phase 3 Interventional

Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment

NCT02962414
View directory record Official record
Conditions
Tuberous Sclerosis Complex
Interventions
everolimus
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 65 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
14
States / cities
Phoenix, Arizona • Los Angeles, California • Oakland, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 31, 2026, 7:54 PM EDT
Completed Phase 2 Interventional

Safety and Tolerability Study of Phenylbutyrate in Huntington's Disease (PHEND-HD)

NCT00212316
View directory record Official record
Conditions
Huntington's Disease
Interventions
sodium phenylbutyrate
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
8
States / cities
Birmingham, Alabama • San Diego, California • Iowa City, Iowa + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2012 · Synced Oct 31, 2026, 7:54 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Sunitinib Malate to Treat Advanced Eye Disease in Patients With Von Hippel-Lindau Syndrome

NCT00673816
View directory record Official record
Conditions
Von Hippel-Lindau Syndrome
Interventions
Sunitinib Malate
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 5, 2024 · Synced Oct 31, 2026, 7:54 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Tailored Patient-Provider Communication (TPPC): Evaluating the Impact of TPPC in Dermatology Patients

NCT04633616
View directory record Official record
Conditions
Psoriasis, Atopic Dermatitis, Acne
Interventions
Tailored Patient-Provider Communication, Non-Tailored Patient-Provider Communication
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 15, 2022 · Synced Oct 31, 2026, 7:54 PM EDT
Completed Phase 2 Interventional Results available

Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD)

NCT01979016
View directory record Official record
Conditions
Atopic Dermatitis (AD)
Interventions
Dupilumab, Placebo, Background treatment
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
Chicago, Illinois • New York, New York • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Oct 31, 2026, 7:54 PM EDT
Recruiting Not applicable Interventional

Stress Management and Mindfulness Intervention for Patients With Sickle Cell Disease

NCT07316478
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Stress Management and Mindfulness Intervention for Patients with Sickle Cell Disease
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 31, 2026, 7:54 PM EDT
Completed No phase listed Observational

Pompe Lactation Sub-Registry

NCT00566878
View directory record Official record
Conditions
Glycogen Storage Disease, Pompe Disease
Interventions
alglucosidase alfa
Biological
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
2
States / cities
Cambridge, Massachusetts • Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Oct 31, 2026, 7:54 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)

NCT03913143
View directory record Official record
Conditions
Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis, Vision Disorders, Sensation Disorders, Neurologic Manifestations, Eye Diseases, Eye Diseases, Hereditary, Eye Disorders Congenital, Retinal Disease
Interventions
sepofarsen, Sham
Drug · Other
Lead sponsor
ProQR Therapeutics
Industry
Eligibility
8 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Oct 31, 2026, 7:54 PM EDT
Completed Not applicable Interventional Results available

VasQ External Support for Arteriovenous Fistula

NCT03242343
View directory record Official record
Conditions
Arterio-Venous Fistula, ESRD, Steal Syndrome, Aneurysm, Renal Failure, Renal Disease, Diabetes Mellitus, Kidney Failure
Interventions
VasQ
Device
Lead sponsor
Laminate Medical Technologies
Industry
Eligibility
18 Years to 80 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
15
States / cities
Birmingham, Alabama • Phoenix, Arizona • Peoria, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 31, 2026, 7:54 PM EDT
Recruiting Phase 1Phase 2 Interventional

Transplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease

NCT04774536
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
CRISPR_SCD001
Drug
Lead sponsor
Mark Walters, MD
Other
Eligibility
12 Years to 35 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
3
States / cities
Davis, California • Los Angeles, California • Oakland, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 31, 2026, 7:54 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Real-Time Assessment of Lung Structure and Function in Children and Young Adults With CF Using Electrical Impedance Tomography

NCT05455671
View directory record Official record
Conditions
Cystic Fibrosis, Healthy
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
3 Years to 21 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Oct 31, 2026, 7:54 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Vascular Fundus Changes in Patients With High Probability of Chronic Cerebrospinal Venous Insufficiency (CCSVI)

NCT01356134
View directory record Official record
Conditions
Ehlers-Danlos Syndrome, Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Genetic Disease Investigators
Other
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Colleyville, Texas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2015 · Synced Oct 31, 2026, 7:54 PM EDT
Completed Phase 1 Interventional

Thymus Transplantation With Immunosuppression

NCT00579709
View directory record Official record
Conditions
DiGeorge Syndrome, DiGeorge Anomaly, Complete DiGeorge Anomaly, Complete DiGeorge Syndrome
Interventions
Thymus Tissue for Transplantation
Biological
Lead sponsor
Sumitomo Pharma Switzerland GmbH
Industry
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 31, 2026, 7:54 PM EDT
Completed Not applicable Interventional

Proactive Speech and Language Intervention for Infants With Down Syndrome

NCT06450509
View directory record Official record
Conditions
Down Syndrome
Interventions
Babble Boot Camp
Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
0 Months to 12 Months
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 31, 2026, 7:54 PM EDT
Recruiting No phase listed Observational

RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT

NCT01885299
View directory record Official record
Conditions
Neoplasms, Arteriovenous Malformation of Central Nervous System, Trigeminal Neuralgia
Interventions
SRS/SBRT
Radiation
Lead sponsor
The Radiosurgery Society
Other
Eligibility
Not listed
Enrollment
50,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2030
U.S. locations
13
States / cities
Colorado Springs, Colorado • Miami, Florida • Brunswick, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 31, 2026, 7:54 PM EDT
Terminated Phase 2 Interventional Results available

Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer

NCT00827099
View directory record Official record
Conditions
Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, fludarabine phosphate, Melphalan, mycophenolate mofetil, tacrolimus, umbilical cord blood transplantation
Biological · Drug · Procedure
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 23, 2012 · Synced Oct 31, 2026, 7:54 PM EDT
Active, not recruiting Not applicable Interventional

Pedi-Cap CO2 Detector for Face-mask Ventilation in the Delivery Room

NCT06258187
View directory record Official record
Conditions
Neonatal Resuscitation, Neonatal Disease
Interventions
Pedi-Cap
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
30 Weeks and older
Enrollment
632 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 31, 2026, 7:54 PM EDT
Completed No phase listed Observational

Tricuspid Regurgitant Jet Velocity as an Independent Marker for Mortality in Sickle Cell Anemia

NCT01783093
View directory record Official record
Conditions
Sickle Cell Anemia, Pulmonary Hypertension
Interventions
Data Collection
Other
Lead sponsor
Namita Sood
Other
Eligibility
18 Years and older
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 31, 2026, 7:54 PM EDT
Terminated Not applicable Interventional Results available

AML Therapy With Irradiated Allogeneic Cells

NCT02105116
View directory record Official record
Conditions
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
fludarabine phosphate, cytarabine, donor lymphocytes, laboratory biomarker analysis, G-CSF
Drug · Biological · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Oct 31, 2026, 7:54 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Genetic Study of the FBN1 Gene and Fibrillin-1 Abnormalities in Choctaw Native Americans and Other Patients With Systemic Sclerosis

NCT00006393
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
0 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1998
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 31, 2026, 7:54 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy of SofWave Treatment to Lift Lax Tissue in the Submental and Neck Zones and to Lift the Eyebrow

NCT04146584
View directory record Official record
Conditions
Skin Laxity, Wrinkle, Brow Lifting
Interventions
Sofwave Treatments
Device
Lead sponsor
Sofwave Medical LTD
Industry
Eligibility
35 Years to 80 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
5
States / cities
Sacramento, California • New York, New York • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Oct 31, 2026, 7:54 PM EDT
Active, not recruiting No phase listed Observational

Long Term Follow Up to Evaluate DTX301 in Adults With Late-Onset OTC Deficiency

NCT03636438
View directory record Official record
Conditions
Ornithine Transcarbamylase (OTC) Deficiency
Interventions
No Intervention
Other
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Timeline
2018 – 2029
U.S. locations
4
States / cities
Aurora, Colorado • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 31, 2026, 7:54 PM EDT